文献速递艾滋病与性传播感染

二价HPV疫苗对型特异性HPV阳性的有效性:荷兰性病门诊就诊者中交叉保护证据

Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
PubMed 文献 · J Infect Dis · 2018-01-01

该研究基于荷兰PASSYON横断面调查,纳入1087名疫苗适龄女性,比较自报接种≥1剂与未接种者的高危HPV阳性率。

要点

  • 对非疫苗型HPV-45、35、31、52分别显示91%、57%、50%、37%的有效性。
  • 对HPV-16/18的保护在接种后5/6年组(92%)与<5年组(83%)相似。

核心结论

  • 二价HPV疫苗对HPV-16/18具有高效性,并对HPV-45/35/31/52显示交叉保护。
  • 对HPV-16/18的保护可持续至接种后6年。

研究设计与样本

  • 基于荷兰性病门诊两年一次横断面调查PASSYON,纳入所有疫苗适龄女性。
  • 共纳入1087名女性,采用PCR法(SPF10-LiPA25)检测阴道拭子12种高危HPV型别。
  • 比较自报接种≥1剂与未接种女性的高危HPV阳性率,采用logistic混合模型估计疫苗有效性。

主要发现

  • 53%的女性高危HPV阳性,60%自报接种疫苗。
  • 对非疫苗型HPV-45有效性91%,HPV-35为57%,HPV-31为50%,HPV-52为37%。
  • 接种后5/6年组对HPV-16/18有效性92%、对所有高危型35%;<5年组分别为83%和33%。

临床怎么用

  • 支持二价HPV疫苗在高风险性病门诊人群中的使用,并提示对部分非疫苗高危型有交叉保护。
  • 接种后至少6年内对HPV-16/18的保护持续存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population. METHODS: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually transmitted infection clinics. Vaginal swabs were analyzed using a polymerase chain reaction-based assay (SPF10-LiPA25) able to detect the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared hrHPV positivity between self-reported vaccinated (≥1 dose) and unvaccinated women, and estimated VE by a logistic mixed model. RESULTS: We included 1087 women of which 53% were hrHPV positive and 60% reported to be vaccinated. The adjusted pooled VE against HPV-16/18 was 89.9% (81.7%-94.4%). Moreover, we calculated significant VE against nonvaccine types HPV-45 (91%), HPV-35 (57%), HPV-31 (50%), and HPV-52 (37%). Among women who were offered vaccination 5/6 years ago, we estimated similar VE against HPV-16/18 (92%) and all hrHPV types (35%) compared to women who were offered vaccination <5 years ago (83% and 33%, respectively). CONCLUSION: We demonstrated high VE of the bivalent vaccine against HPV-16/18 and cross-protection against HPV-45/35/31/52. Protection against HPV-16/18 was sustained up to 6 years postvaccination.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Woestenberg PJ, King AJ, van Benthem BHB, et al. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors. J Infect Dis. 2018. PMID: 29140439. doi:10.1093/infdis/jix582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。